MHRA and Barts Health NHS Trust Implement Rapid DNA Sequencing to Expedite Infection Diagnosis
In a pioneering collaboration, the Medicines and Healthcare products Regulatory Agency (MHRA) and Barts Health NHS Trust have developed a DNA sequencing method that allows hospitals to diagnose bacterial infections more rapidly and accurately. This advancement facilitates earlier, targeted treatments, leading to quicker patient recoveries and a reduction in complications such as sepsis.
Introduction:
Accurate and timely diagnosis of bacterial infections is crucial for effective patient care. Traditional diagnostic methods can take up to seven days, or even eight weeks in complex cases, often resulting in the use of broad-spectrum antibiotics that may not be optimally effective and can contribute to antimicrobial resistance. To address this challenge, the MHRA and Barts Health NHS Trust have collaborated to implement a rapid DNA sequencing service within hospital settings, aiming to enhance diagnostic speed and precision.
Key Features of the New DNA Sequencing Approach:
- Accelerated Diagnosis:
The new method delivers results within two days, a significant improvement over traditional techniques that can take up to seven days or longer. - Onsite Implementation:
The DNA sequencing service is integrated within hospital laboratories, allowing for immediate analysis of patient samples without the need for external processing. - Enhanced Accuracy:
By reading the genetic code of bacteria, this approach accurately identifies the specific pathogens causing an infection and determines their antibiotic susceptibilities, facilitating targeted treatment strategies. - Pilot Programme Success:
Since September 2024, over 2,000 patient samples have been analysed using this method across seven London hospitals, including the Royal London, Whipps Cross, Newham, St Bartholomew’s, Homerton, Lewisham, and Greenwich.
Implications for Patient Care:
- Timely Treatment:
Faster diagnosis enables healthcare providers to administer appropriate antibiotics sooner, reducing the risk of complications and promoting quicker recoveries.​ - Combatting Antimicrobial Resistance:
Accurate identification of pathogens allows for the use of targeted antibiotics, decreasing reliance on broad-spectrum antibiotics and helping to mitigate the development of antimicrobial resistance.​ - Outbreak Prevention:
The technology is being piloted to investigate and prevent hospital outbreaks caused by antibiotic-resistant ‘superbugs’, enhancing infection control measures within healthcare settings.
Conclusion:
The collaboration between the MHRA and Barts Health NHS Trust represents a significant advancement in the diagnosis and management of bacterial infections. By integrating rapid DNA sequencing into hospital laboratories, this initiative not only improves individual patient outcomes but also strengthens the broader public health response to antimicrobial resistance. The success of the pilot programme paves the way for potential nationwide adoption across the NHS, offering a model for innovative healthcare solutions.
Recent Resources
